Clinical trials
catalyst calendar across sponsors →Studies where OTLK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 3 with posted results
Held by 5 tracked-famous managers (MARSHALL WACE, LLP, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, Ancora Advisors LLC) · FINRA short interest 1.1 days to cover (settled 2026-07-31) · insider 90d: 6 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersNCT05112861Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFSOpen-label · Treatment | Phase 3 | Active, not recruiting | Biological: bevacizumab | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 120 | Dec 2027 | ≤ 498 d | 2026-04-22 |
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT06190093results2026-06-30Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration | 400 | 2024-11-07actual | — | 2026-07-23 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03834753results2026-08-03Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 228 | 2021-06-07actual | — | 2026-08-03 |
| A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersNCT04516278results2026-07-17Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: bevacizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 197 | 2021-02-10actual | — | 2026-07-17 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03844074Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: bevacizumab, ranibizumab | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | 61 | 2020-07-23actual | — | 2025-03-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19